Top

Published in:

01-09-2019 | Laser | Original Article

A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy

Authors: Lijun Zhou, Victor Chong, Kunbei Lai, Chuangxin Huang, Fabao Xu, Yajun Gong, Maimaitiaili Youlidaxi, Tao Li, Lin Lu, Chenjin Jin

Published in: Lasers in Medical Science | Issue 7/2019

Abstract

To compare the efficacy of 50% threshold power with 25% threshold power of 577-nm subthreshold micropulse laser (SMPL) for acute central serous chorioretinopathy (CSC). Prospective, interventional, non-randomized, comparative case series. A total of 54 patients (54 eyes) with acute CSC were enrolled. Twenty-four eyes received 25% threshold power and 30 eyes received 50% threshold power of 577-nm SMPL. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and complete absorption of subretinal fluid (SRF) were evaluated at 1 month and 3 months. The complete absorption rate of SRF in the 50% power group was significantly greater than that in the 25% power group at 1 month (70.0% vs 25.0%, p < 0.001) and at 3 months (83.3% vs 54.2%, p < 0.001). Mean BCVA improved from 0.34 ± 0.20 LogMAR to 0.02 ± 0.13 LogMAR in the 50% power group and from 0.27 ± 0.15 LogMAR to 0.14 ± 0.21 LogMAR in the 25% power group with a significant difference between the two groups after 3 months (p = 0.027). In the 50% power group, the CMT decreased from 491.6 ± 154.8 μm at baseline to 231.3 ± 92.3 μm at 1 month and 228.2 ± 88.1 μm at 3 months, and in the 25% power group, the CMT decreased from 444.9 ± 164.1 to 306.8 ± 102.6 μm at 1 month and 254.5 ± 101.7 μm at 3 months. There was statistical difference of CMT at 1 month (p = 0.009) but no significant difference at 3 months between the two groups (p = 0.232). SMPL with 50% threshold power may be more effective than 25% threshold power for acute CSC.

An SH, Kwon YH (2016) Effect of a topical nonsteroidal anti-inflammatory agent (0.1% pranoprofen) on acute central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 254(8):1489–1496. https://doi.org/10.1007/s00417-015-3215-8 CrossRefPubMed

Wong KH, Lau KP, Chhablani J, Tao Y, Li Q, Wong IY (2016) Central serous chorioretinopathy: what we have learnt so far. Acta Ophthalmol 94(4):321–325. https://doi.org/10.1111/aos.12779 CrossRefPubMed

Yannuzzi LA (1987) Type-A behavior and central serous chorioretinopathy. Retina 7(2):111–131CrossRefPubMed

Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118. https://doi.org/10.1016/j.preteyeres.2015.05.003 CrossRefPubMed

Iacono P, Battaglia Parodi M, Falcomata B, Bandello F (2015) Central serous chorioretinopathy treatments: a mini review. Ophthalmic Res 55(2):76–83. https://doi.org/10.1159/000441502 CrossRefPubMed

Loo RH, Scott IU, Flynn HW Jr, Gass JD, Murray TG, Lewis ML, Rosenfeld PJ, Smiddy WE (2002) Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 22(1):19–24CrossRefPubMed

Fok AC, Chan PP, Lam DS, Lai TY (2011) Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res 46(3):160–163. https://doi.org/10.1159/000324599 CrossRefPubMed

Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology 115(1):169–173. https://doi.org/10.1016/j.ophtha.2007.02.032 CrossRefPubMed

Chan WM, Lai TY, Lai RY, Liu DT, Lam DS (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115(10):1756–1765. https://doi.org/10.1016/j.ophtha.2008.04.014 CrossRefPubMed

10.

Khosla PK, Rana SS, Tewari HK, Azad RU, Talwar D (1997) Evaluation of visual function following argon laser photocoagulation in central serous retinopathy. Ophthalmic Surg Lasers 28(8):693–697PubMed

11.

Zhao MW, Zhou P, Xiao HX, Lv YS, Li CA, Liu GD, Li XX (2009) Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin. Retina 29(8):1155–1161. https://doi.org/10.1097/IAE.0b013e3181a6c028 CrossRefPubMed

12.

Schatz H, Yannuzzi LA, Gitter KA (2012) Subretinal neovascularization following argon laser photocoagulation treatment for central serous chorioretinopathy: complication or misdiagnosis? 1975. Retina 32(Suppl 1):OP893–OP906CrossRefPubMed

13.

Koytak A, Erol K, Coskun E, Asik N, Ozturk H, Ozerturk Y (2010) Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy. Retina 30(10):1698–1703. https://doi.org/10.1097/IAE.0b013e3181da4354 CrossRefPubMed

14.

Kim SW, Oh J, Oh IK, Huh K (2009) Retinal pigment epithelial tear after half fluence PDT for serous pigment epithelial detachment in central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 40(3):300–303CrossRefPubMed

15.

Sivaprasad S, Elagouz M, McHugh D, Shona O, Dorin G (2010) Micropulsed diode laser therapy: evolution and clinical applications. Surv Ophthalmol 55(6):516–530. https://doi.org/10.1016/j.survophthal.2010.02.005 CrossRefPubMed

16.

Kwon YH, Lee DK, Kwon OW (2014) The short-term efficacy of subthreshold micropulse yellow (577-nm) laser photocoagulation for diabetic macular edema. Korean J Ophthalmol 28(5):379–385. https://doi.org/10.3341/kjo.2014.28.5.379 CrossRefPubMedPubMedCentral

17.

Ohkoshi K, Yamaguchi T (2010) Subthreshold micropulse diode laser photocoagulation for diabetic macular edema in Japanese patients. Am J Ophthalmol 149(1):133–139. https://doi.org/10.1016/j.ajo.2009.08.010 CrossRefPubMed

18.

Yadav NK, Jayadev C, Rajendran A, Nagpal M (2014) Recent developments in retinal lasers and delivery systems. Indian J Ophthalmol 62(1):50–54. https://doi.org/10.4103/0301-4738.126179 CrossRefPubMedPubMedCentral

19.

Yadav NK, Jayadev C, Mohan A, Vijayan P, Battu R, Dabir S, Shetty B, Shetty R, Medscape (2015) Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome. Eye (Lond) 29(2):258–264; quiz 265. https://doi.org/10.1038/eye.2014.315 CrossRef

20.

Scholz P, Altay L, Fauser S (2016) Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy. Eye (Lond). https://doi.org/10.1038/eye.2016.142

21.

Kim JY, Park HS, Kim SY (2015) Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 253(12):2129–2135. https://doi.org/10.1007/s00417-015-2965-7 CrossRefPubMed

22.

Roisman L, Magalhaes FP, Lavinsky D, Moraes N, Hirai FE, Cardillo JA, Farah ME (2013) Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg Lasers Imaging Retina 44(5):465–470. https://doi.org/10.3928/23258160-20130909-08 CrossRefPubMed

23.

Sun X, Shuai Y, Fang W, Li J, Ge W, Yuan S, Liu Q (2017) Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2017-311096

24.

Lavinsky D, Sramek C, Wang J, Huie P, Dalal R, Mandel Y, Palanker D (2014) Subvisible retinal laser therapy: titration algorithm and tissue response. Retina 34(1):87–97. https://doi.org/10.1097/IAE.0b013e3182993edc CrossRefPubMed

25.

Lavinsky D, Palanker D (2015) Nondamaging photothermal therapy for the retina: initial clinical experience with chronic central serous retinopathy. Retina 35(2):213–222. https://doi.org/10.1097/IAE.0000000000000340 CrossRefPubMed

26.

Maruko I, Koizumi H, Hasegawa T, Arakawa H, Iida T (2017) Subthreshold 577 nm micropulse laser treatment for central serous chorioretinopathy. PLoS One 12(8):e0184112. https://doi.org/10.1371/journal.pone.0184112 CrossRefPubMedPubMedCentral

Title: A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy
Authors: Lijun Zhou
Victor Chong
Kunbei Lai
Chuangxin Huang
Fabao Xu
Yajun Gong
Maimaitiaili Youlidaxi
Tao Li
Lin Lu
Chenjin Jin
Publication date: 01-09-2019
Publisher: Springer London
Keyword: Laser
Published in: Lasers in Medical Science / Issue 7/2019
Print ISSN: 0268-8921
Electronic ISSN: 1435-604X
DOI: https://doi.org/10.1007/s10103-019-02721-8

At a glance: The STEP trials

Springer Medicine

A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2019

Minimally invasive erbium laser treatment for selected snorers

Effects of 1064-nm Nd:YAG long-pulse laser on polidocanol microfoam injected for varicose vein treatment: a controlled observational study of 404 legs, after 5-year-long treatment

In vitro effect of low-level laser therapy on the proliferative, apoptosis modulation, and oxi-inflammatory markers of premature-senescent hydrogen peroxide-induced dermal fibroblasts

Efficacy of low-level laser therapy in pain management after root canal treatment or retreatment: a systematic review

Comparative study between the efficacy of fractional micro-needle radiofrequency and fractional CO2 laser in the treatment of striae distensae

Effects of low-level laser therapy on the organization of articular cartilage in an experimental microcrystalline arthritis model